oncnursingnews15 天
Lung Cancer
Patients receiving ponsegromab experienced significantly greater weight gain and physical activity than those receiving placebo.
新浪网24 天
全球TOP 20药企榜单出炉！都有哪些公司入选？
潜在“first-in-class”抗体偶联药物telisotuzumab vedotin有望获批治疗c-Met蛋白过度表达的经治局部晚期或转移性非鳞状NSCLC成人患者。 诺和诺德（Novo Nordisk ...
生物通1 个月
综述：非小细胞肺癌（NSCLC）中 MET 作为治疗靶点的研究进展
抗 MET ADC：ADCs 通过将抗体与细胞毒性药物连接，实现对肿瘤细胞的靶向杀伤。Telisotuzumab vedotin 是首个开发的抗 MET ADC，在针对 MET 表达的鳞状细胞肺癌的 Lung - MAP S1400K 试验中，因疗效不佳而终止。但在与 EGFR 抑制剂联合治疗 EGFR 突变且 MET 表达的 NSCLC 患者的研究 ...
National Institute for Health and Care Excellence1 个月
In development: Guidance, quality standards and advice
PIK3CA-positive breast cancer in postmenopausal women ID1401 Technology appraisal guidance TBC Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced ...
National Institute for Health and Care Excellence1 个月
In development: Guidance, quality standards and advice
PIK3CA-positive breast cancer in postmenopausal women ID1401 Technology appraisal guidance TBC Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced ...
pharmaphorum1 个月
AbbVie agrees $10.1bn deal to buy ImmunoGen
News of the ImmunoGen play comes shortly after the company reported new clinical results for telisotuzumab vedotin (Teliso-V) ADC in patients with relapsed or refractory non-squamous, non-small ...